Biotech Stocks Mired in Uncertainty: China Deal, Drug Pricing Politics and Earnings Outlook…Update-2 Rally Day
Update-2 10/13...Biotech IPOs Remain Weak-Recent rally was weak for small cap biotechs Vir Biotechnology (VIR): A clinical stage immunology and infectious disease Company focused on new therapies for hepatitis (HBV), Influenza A, HIV and TB went public on Friday. Despite aa broad experienced...
Large Cap Biopharma in Focus: Core Positions…Risk OFF…Updates
10/09/19 Better tape today but a lot of random churning and tactical trading, biopharma under siege? NASDAQ up 1.17%. Talk about mini-deal with China. Large cap leaders with IBB flat: REGN MRK BMY. Mid caps weak with XBI down 0.63%. JNJ woes continue with $8B verdict on Risperdal, stock down 2%...
Biotech Snapshot: Bears Are Digging In…Update-2… Upside Reversal
Update-2 10/4 Broad Rally day: all major averages up 1.4%, NAZ at 7982. Risk back on. But biotech lags major indices IBB up 0.75%, XBI up 0.21% to $76.82. Better trade for biotech has been large caps: ABBV, AMGN, MRK,RHHBY VRTX. Mid-cap movers: BLUE up 3.97%, GWPH up 5.22%, NKTR up 4.2%, SRPT...
Biopharma Stocks Mired in Macro-Risk Off…Update-2…”Future of Biotech” from Barrons’s
With biotech in a funk this timely article from Barron's should help. Barron's to the Rescue: Future of Biotech, article offers picks from a new Roundtable (above link may not open because requires subscription) Some of the picks ASND, MDCO,MGTX,NVTA,RGNX, SRPT, VRTX ========= Update-2 9/28...
What Did I Miss While I was on Vacation in September: Biotech Wrap-Up in a Sideways Market…Update-1
Update-1 A bit of a sell-off on end of week option expirations and cancellation of China visit to farm Bureau in MT. NAZ down 0.8%, S&P down 0.5%. Less reaction to China news now? Can biotech rally as contrian play to tech and industrials? tape in biotech was better than overall market....